2月12日,$LLY(LLY)礼来制药宣布,其GLP-1R/GIPR双重激动剂 替尔泊肽 在国内获批成人2型糖尿病(T2DM)单药治疗新适应症。更新后的说明书同步扩容,覆盖从单药到联合多种降糖药的全场景应用——在饮食控制与运动基础上,均可用于改善成人T2DM患者的血糖控制。截图来源:企业官微这意味着,替尔泊肽 在中国糖尿病治疗路径上实现“单药起始→联合强化”的完整闭环,为不同病情阶段患者提供灵活...
Source Link2月12日,$LLY(LLY)礼来制药宣布,其GLP-1R/GIPR双重激动剂 替尔泊肽 在国内获批成人2型糖尿病(T2DM)单药治疗新适应症。更新后的说明书同步扩容,覆盖从单药到联合多种降糖药的全场景应用——在饮食控制与运动基础上,均可用于改善成人T2DM患者的血糖控制。截图来源:企业官微这意味着,替尔泊肽 在中国糖尿病治疗路径上实现“单药起始→联合强化”的完整闭环,为不同病情阶段患者提供灵活...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.